New Treatments for Familial Chylomicronemia Syndrome (FCS)
Health ConditionsRare Diseases

Treatments for Familial Chylomicronemia Syndrome (FCS) You May Not Have Heard About

Treatments for Familial Chylomicronemia Syndrome (FCS) You May Not Have Heard About
Adobe Stock (2)
By
Published on October 31, 2025
by
Familial chylomicronemia syndrome (FCS) is a rare genetic disorder that causes extremely high triglyceride (fat) levels in the blood. Common symptoms include abdominal pain from pancreatitis, enlargement of the liver and spleen, yellow fat deposits in the skin, and a creamy appearance of the blood vessels in the eye.

 FCS is typically treated with diet restrictions.

 “The most important lifestyle factor [in FCS] is a strict low-fat diet,” says David H. Hsi, MD, chief of cardiology and co-director of the Heart and Vascular Institute at Stamford Health in Connecticut.
But the U.S. Food and Drug Administration (FDA) has approved one medication for FCS, and experts are researching other emerging treatments. These new medications block activity that leads to high triglyceride levels and, once approved, could offer life-changing symptom improvement for people with this disorder.

 If you want to try a new familial chylomicronemia syndrome treatment, check with your healthcare team first, who can direct you to available options.

FDA-Approved Medications

Olezarsen (Tryngolza), the first and only FDA-approved medication for the treatment of FCS, works by blocking the production of apolipoprotein C3 (a protein that inhibits the breakdown of fat), which allows your body to break down fats more easily, says Dr. Hsi.

“In our clinic, olezarsen has been effective in decreasing triglycerides,” says Ashish Sarraju, MD, preventive cardiologist at Cleveland Clinic in Ohio. “The hope is that this will translate to reduced risk of pancreatitis (a common complication of FCS) moving forward.”

Olezarsen is to be used along with a low-fat diet, and is given as an injection in the fatty part of the abdomen or thigh once a month. Sometimes injections can cause hypersensitivity reactions, which include side effects like swelling, itching, chills, muscle pain, and difficulty breathing.

As a new medication, olezarsen isn’t always available at local pharmacies, says Dr. Sarraju. But your provider can help. After confirming an FCS diagnosis, providers have to work through insurance coverage, which may not be straightforward, says Sarraju. “So, it is important for patients to stay in close touch with their doctors to navigate the insurance.”

Emerging Treatments

Although the FDA has only approved olezarsen so far, other investigational therapies are being evaluated in clinical trials. “I am excited about therapies that target apolipoprotein C3 and ANGPTL3 as mechanisms to improve triglycerides,” says Sarraju, as both of these proteins stop effective fat breakdown.

Plozasiran (ARO-APOC3)

An experimental drug called plozasiran works by suppressing the genes for apolipoprotein C3, allowing the body to flush out more fat. In a current clinical trial set to wrap up in 2026, 75 people with FCS have had up to an 80 percent decrease in triglyceride levels after taking plozasiran for 10 months.

So far, participants have reported few side effects, but some experienced abdominal pain, sinus inflammation, headache, and nausea.

Gene Editing Therapies

Sometimes FCS is caused by a problem with the ANGPTL3 gene, which gives the ANGPTL3 protein its operating instructions.

 Researchers are studying methods to change how these genes work using a technique called CRISPR, stopping triglyceride-boosting proteins at their source.

This treatment option is still in its early stages, and animal studies show promise; however, human trials are needed before gene editing can be used to treat FCS.

ANGPTL3 Inhibitors

Some emerging medications bypass the genetic component and target the ANGPTL3 protein itself. For example, monoclonal antibodies (proteins made in a lab) attach to specific materials, like ANGPTL3, and destroy them.

Monoclonal antibodies being studied for FCS treatment include evinacumab and vupanorsen. Evinacumab was shown to significantly lower LDL levels in phase 3 trials, and vupanorsen reduced triglycerides by up to 53 percent in a phase 2 trial.

Zodasiran and solbinsiran (siRNA therapies) are another type of ANGPTL3 inhibitor. In phase 2 clinical trials, zodasiran lowered triglycerides by up to about 63 percent, and preliminary trials of solbinisiran demonstrated a reduction of triglycerides by 73 percent.

Orlistat (Xenical)

Orlistat (Xenical) prevents the intestines from absorbing some of the fats you eat.

 Typically used for obesity treatment, orlistat may also decrease triglyceride levels in FCS.

One small study of two children found orlistat lowered triglycerides by up to 62 percent.

 In another case study on a 35-year-old woman, treatment with orlistat lowered triglyceride levels and reduced hospital admissions for pancreatitis.

When taking orlistat, it’s important to restrict your fat intake, which can cause side effects like excess gas and loose stools. Your body needs some fat to function, and your provider may also recommend taking fat-soluble vitamins to prevent nutrient deficiencies.

Joining a Clinical Trial

Many of these developing treatment options are offered in ongoing clinical trials, which allow people with FCS to try new medications before they’re available to the public. Your provider can help you find ongoing trials and connect you with experts in that field, says Sarraju.

“Any patients with FCS should seek specialized care in lipid management, such as a certified dietitian and lipid specialist," says Hsi. Another good source of information on emerging treatments is ClinicalTrials.gov, an online research database maintained by the U.S. government. Here, you can search for studies on FCS or specific treatments, find out what stage of the process they’re in, and discover trials currently accepting applicants.

The Takeaway

  • Familial chylomicronemia syndrome is primarily treated with a very low-fat diet, but the FDA has recently approved a drug called olezarsen (Tryngolza), which can work alongside diet to decrease FCS symptoms and complications.
  • Some emerging treatments target the proteins that cause FCS, and others edit the DNA responsible for encoding these proteins.
  • If you’re interested in joining a clinical trial for an FCS medication that’s not yet available to the public, you can find ongoing trials at ClinicalTrials.gov.

Resources We Trust

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Metkus TS et al. Chylomicronemia Syndrome. MedlinePlus. May 8, 2024.
  2. Regmi M et al. Familial Hyperchylomicronemia Syndrome. StatPearls. August 8, 2023.
  3. Izar MC et al. Novel Therapeutics for Familial Chylomicronemia Syndrome. Current Atherosclerosis Reports. April 21, 2025.
  4. FDA Approves Drug to Reduce Triglycerides in Adult Patients With Familial Chylomicronemia Syndrome. U.S. Food and Drug Administration. December 19, 2024.
  5. Tryngolza (Olezarsen) Prescribing Information. U.S. Food and Drug Administration. 2024.
  6. Watts GF et al. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. The New England Journal of Medicine. April 21, 2025.
  7. Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) (PALISADE). Clinicaltrials.gov. April 30, 2025.
  8. ANGPTL3 Angiopoietin Like 3. National Center for Biotechnology Information. August 19, 2025.
  9. Khera A et al. An in Vivo CRISPR Base Editing Therapy to Inactivate the ANGPTL3 Gene: Nomination of a Development Candidate for Verve-201. European Heart Journal. October 2022.
  10. Chadwick AC et al. Reduced Blood Lipid Levels with In Vivo CRISPR-Cas9 Base Editing of ANGPTL3. Circulation. February 27, 2018.
  11. Monoclonal Antibodies. Cleveland Clinic. November 16, 2021.
  12. Orlistat. MedlinePlus. July 20, 2024.
  13. Javed F et al. Familial Chylomicronemia Syndrome: An Expert Clinical Review From the National Lipid Association. Journal of Clinical Lipidology. June 23, 2025.
  14. Patni N et al. Orlistat Therapy for Children With Type 1 Hyperlipoproteinemia: A Randomized Clinical Trial. The Journal of Clinical Endocrinology & Metabolism. April 5, 2018.
  15. Jarrett ZS et al. The Use of Orlistat in an Adult with Lipoprotein Lipase Deficiency: A Case Report. AACE Clinical Case Reports. March 17, 2022.
Meet Our Experts
See Our Editorial PolicyMeet Our Health Expert Network
joy-tanaka-bio

Joy Tanaka, PhD

Medical Reviewer

Joy Tanaka, PhD, specializes in clinical molecular genetics. She is dedicated to integrating excellent clinical care with cutting-edge medical research for patients with rare and undiagnosed disorders, and is focused on pursuing questions at the interface between genetics and human disease with the goal of developing novel therapies and treatments.

Dr. Tanaka received her PhD from Yale University School of Medicine, where she was a Howard Hughes Medical Institute Medical Research Scholar and recipient of the George Robert Pfeiffer Fellowship for Translational Medicine. She completed her clinical fellowship in cytogenetics and clinical molecular genetics at Columbia University and New York Presbyterian Hospital, and is currently associate clinical laboratory director at Rady Children's Hospital Institute for Genomic Medicine in San Diego, California.

See full bio

Abby McCoy, RN

Author

Abby McCoy is an experienced registered nurse who has worked with adults and pediatric patients encompassing trauma, orthopedics, home care, transplant, and case management. She is a married mother of four and loves the circus — that is her home! She has family all over the world, and loves to travel as much as possible.

McCoy has written for publications like Remedy Health Media, Sleepopolis, and Expectful. She is passionate about health education and loves using her experience and knowledge in her writing.

See full bio
See Our Editorial PolicyMeet Our Health Expert Network